Pr ecis: The efficacy of hundreds of dendritic cell vaccines currently in clinical development might be improved dramatically simply by reducing the oxygen level in tumor cell cultures that are used as source of antigens to prime the vaccine. Pr ecis: Findings offer a straightforward strategy to enhance the potency of dendritic cell vaccines, for which Provenge is the first FDA-approved example, by targeting a pattern recognition scavenger receptor that limits the ability of dentritic cells to restore T cell-mediated antitumor immunity.
Pr ecis: JAK inhibitors in clinical development effectively inhibit tumor angiogenesis and metastasis mediated by STAT3 in tumor stromal cells as well as tumor cells themselves, encouraging their broader evaluation for cancer treatment than only in malignancies characterized by JAK/STAT mutations.
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Human Breast Tumor Cells Induce Self-Tolerance Mechanisms to Avoid NKG2D-Mediated and DNAM-Mediated NK Cell Recognition Emilie Mamessier, Aude Sylvain, François Bertucci, R emy Castellano, Pascal Finetti, Gilles Houvenaeghel, Emmanuelle Charaffe-Jaufret, Daniel Birnbaum, Alessandro Moretta, and Daniel Olive Pr ecis: All breast cancer subtypes develop mechanisms to escape natural killer cell-mediated immune recognition, rationalizing the development of immunotherapies that can relieve escape and/or enhance natural killer cell function. 
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